A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

Part of paid clinical trials in Anaheim, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07283263
Phase
PHASE1
Status
Recruiting

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • BMS-985521 — DRUG
    Specified dose on specified days.
  • Placebo — OTHER
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.

Key Dates

Start date
Dec 23, 2025
Status verified
Jan 2026
Primary completion
Nov 17, 2026
Completion
Nov 17, 2026

Study Design

Enrollment
106 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A Cohort 1
  • Experimental: Part A Cohort 2
  • Experimental: Part A Cohort 3
  • Experimental: Part A Cohort 4
  • Experimental: Part A Cohort 5
  • Experimental: Part A Cohort 6
  • Experimental: Part B Cohort 7
  • Experimental: Part B Cohort 8
  • Experimental: Part B Cohort 9
  • Experimental: Part B Cohort 10
  • Experimental: Part B Cohort 11
  • Experimental: Part C

Primary Outcome Measure

Number of participants with treatment-emergent adverse events (AEs) [ Time Frame: Up to approximately Day 40 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
  • First line of the email MUST contain the NCT# and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)AnaheimCalifornia92801
Peter Winkle, Site 0001
949-295-7809

Find similar trials in Anaheim, CA

Related Studies